


# Second Quarter 2023 Results Call Corporate Update & Financial Results

August 3, 2023



# Forward-Looking Statements



BioCryst’s presentation may contain forward-looking statements, including statements regarding future results, unaudited and forward-looking financial information and company performance or achievements. These statements are subject to known and unknown risks and uncertainties which may cause our actual results, performance or achievements to be materially different from any future results or performances expressed or implied in this presentation. You should not place undue reliance on the forward-looking statements. For additional information, including important risk factors, please refer to BioCryst’s documents filed with the SEC and located at <https://ir.biocryst.com/financial-information/sec-filings>.

# Agenda

- ◆ Corporate Update:

Jon Stonehouse – President and Chief Executive Officer

- ◆ ORLADEYO® (berotralstat) Launch Update:

Charlie Gayer – Chief Commercial Officer

- ◆ Pipeline Update:

Dr. Helen Thackray – Chief Research and Development Officer

- ◆ Financial Update:

Anthony Doyle – Chief Financial Officer


Q&A

# Orladeyo Pediatric Trial Enrollment Ongoing

***New granule formulation designed to reduce burden of therapy for children with HAE***

## Trial Details

- Ages 2 to <12
- Enrollment of approximately 20 patients (4 cohorts)
- 12-week standard-of-care therapy, followed by open-label treatment period
- Primary endpoint: Characterization of the PK profile of ORLADEYO in patients aged 2 to <12 years



# Debt Refinancing: Better Terms, Longer Maturity, Larger Principal

|  | New Terms (Pharmakon)                          | Prior Terms (Athyrium)                                       |
|--|--|--|
| <b>Principal Drawn</b>                           | \$300M   | \$200M   |
| <b>Tranches Available</b><br>(at company option) | \$150M<br>(through September 2024)             | None   |
| <b>Rate</b>                                      | 3 mo. SOFR + 7.00%<br>With PIK option: + 7.25% | 3 mo. LIBOR (3.50% cap) + 8.25%<br>With PIK option: + 10.25% |
| <b>Maturity</b>                                  | April 2028                                     | December 2025  |
| <b>Financial Covenants</b>                       | None   | Minimum liquidity \$15M                                      |
| <b>PIK option</b>                                | 50% of interest for first six quarters         | Ended Q4 2022  |

- Puts company on strong financial footing to drive ORLADEYO® revenue toward \$1B peak
- Bullet payment moved to 2028
- Pro forma net cash increased \$26M after repayment of Athyrium debt
- Dramatically reduces company's dependence on capital markets

# Finance Summary

(figures in millions)

## Q2 2023 Cash Position

|  |       |
|--|-------|
| Cash, cash equivalents, restricted cash & investments at December 31, 2022 | \$444 |
| Cash, cash equivalents, restricted cash & investments at June 30, 2023     | \$416 |
| Senior credit facility <sup>A</sup>  | \$304 |

## 2023 FY Guidance

|  |        |
|--|--------|
| ORLADEYO <sup>®</sup> revenue                | ≥\$320 |
| Operating expenses (excluding non-cash comp) | \$375  |

A – From Pharmakon Advisors, financing of \$450M (\$300M drawn at issuance) with PIK option for 50% of interest for first six quarters; \$3.8M in interest payment-in-kind added to principal since issuance through June 30, 2023; \$150M remaining available to draw at company's option through September 2024



*Save the Date:*

# BioCryst Pharmaceuticals R&D Day

November 3, 2023

# Second Quarter 2023 Results Call Corporate Update & Financial Results

August 3, 2023

